. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Contrast Media Mol Imaging. 2014 Jun 27;10(2):135–143. doi: 10.1002/cmmi.1609

Table 1.

Characterization of PNA-immobilized and lectin-free fluorescent nanospheres.

Characterization	PNA-immobilized fluorescent nanospheres	Lectin-free fluorescent nanospheres with PNVA and PMAA chains	Lectin-free fluorescent nanospheres with PNVA chains
Molecular weight of PNVA (Mw/Mn)	→	9500/4000	9500/4000
Molecular weight of PMAA (Mw/Mn)	→	10000/5600	-^h
Particle size (nm)^a	-^g	302 ± 80	384 ± 90
Zeta potential (mV)^b	-^g	-21.8	-2.8
Encapsulated coumarin 6 (μg/mg)^c	→	0.8	1.0
Immobilized PNA (μg/mg)^d	6.6	-^h	-^h
Minimum conc. of PNA for agglutination of neuraminidase-treated erythrocytes (μg/mL)^e	0.032	-^h	-^h
Minimum conc. of PNA for agglutination of neuraminidase-untreated erythrocytes (μg/mL)^f	>33.0	-^h	-^h

Weight-average diameter (mean ± s.d.)

Measured in neutral PBS (without CaCl₂ and MgCl₂) at 25°C

Encapsulated amount (μg) of coumarin 6 per milligram of the imaging agent and its precursor.

Immobilized amount (μg) of PNA per milligram of the imaging agent.

Minimum concentration of PNA immobilized on the nanospheres surface that induced neuraminidase-treated (Gal-β(1-3)GalNAc-expressed) erythrocyte agglutination.

Minimum concentration of PNA immobilized on the nanospheres surface that induced neuraminidase-untreated erythrocyte agglutination.

Not tested

Not required